SAN DIEGO — AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, a strategic move aimed at enhancing its pipeline with an atopic dermatitis candidate poised for Phase III trials later this year. This acquisition positions AbbVie to potentially challenge leading therapies in the immunology space, particularly in light of the competitive landscape surrounding atopic dermatitis treatments.
Apogee’s lead candidate, zumilokibart, is an IL-13 inhibitor that demonstrates significant promise due to its long-acting formulation and potential applications across various immunological conditions. Analysts have noted that its dosing regimen, which may allow administration every three to six months, could distinguish it from existing therapies, notably Dupixent, which currently dominates the market.
The acquisition underscores AbbVie’s commitment to expanding its immunology portfolio, particularly as it navigates the loss of exclusivity for its blockbuster drug Humira. With recent positive data from Apogee’s clinical trials, the integration of zumilokibart could bolster AbbVie’s competitive edge in the immunology market, particularly against established players like Sanofi and Regeneron.
As AbbVie prepares for the acquisition’s closure, anticipated in the third quarter pending regulatory approvals, the move reflects a broader trend in biopharma where strategic acquisitions are increasingly viewed as essential for sustaining innovation and market leadership in a rapidly evolving landscape.
Open the full market picture for your next decision →
